Adam J Dupuy
Overview
Explore the profile of Adam J Dupuy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
2977
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fan J, Erickson A, Carrillo-Garcia J, Wang X, Skowron P, Wang X, et al.
Dev Cell
. 2025 Jan;
PMID: 39862856
Distinguishing tumor maintenance genes from initiation, progression, and passenger genes is critical for developing effective therapies. We employed a functional genomic approach using the Lazy Piggy transposon to identify tumor...
2.
Riordan J, Nathanson T, Varzavand A, Hawkins A, Peplinski R, Hannan E, et al.
bioRxiv
. 2025 Jan;
PMID: 39764000
The Rac1 P29S hotspot mutation in cutaneous melanoma is associated with resistance to MAPK pathway inhibitors (MAPKi) and worse clinical outcomes. Moreover, activation of Rac1 guanine exchange factors (GEFs) also...
3.
Schillo J, Feddersen C, Peplinski R, Powell L, Varzavand A, Stipp C, et al.
NAR Cancer
. 2024 Jan;
6(1):zcad061.
PMID: 38213996
The evolution of therapeutic resistance is a major obstacle to the success of targeted oncology drugs. While both inter- and intratumoral heterogeneity limit our ability to detect resistant subpopulations that...
4.
Zhu E, Schillo J, Murray S, Riordan J, Dupuy A
iScience
. 2023 Oct;
26(10):107805.
PMID: 37860756
Combined BRAF and MEK inhibition is an effective treatment for BRAF-mutant cutaneous melanoma. However, most patients progress on this treatment due to drug resistance. Here, we applied the transposon system...
5.
Zhu E, Riordan J, Vanneste M, Henry M, Stipp C, Dupuy A
NPJ Precis Oncol
. 2022 Oct;
6(1):74.
PMID: 36271142
Rare gain-of-function mutations in RAC1 drive drug resistance to targeted BRAF inhibition in cutaneous melanoma. Here, we show that wildtype RAC1 is a critical driver of growth and drug resistance,...
6.
Vaishnavi A, Juan J, Jacob M, Stehn C, Gardner E, Scherzer M, et al.
Cancer Res
. 2022 Sep;
82(22):4261-4273.
PMID: 36112789
Significance: Loss of RBMS3 cooperates with BRAFV600E to induce lung tumorigenesis, providing a deeper understanding of the molecular mechanisms underlying mutant BRAF-driven lung cancer and potential strategies to more effectively...
7.
Zhu E, Dupuy A
BMC Bioinformatics
. 2022 May;
23(1):184.
PMID: 35581546
Background: The mechanism of action for most cancer drugs is not clear. Large-scale pharmacogenomic cancer cell line datasets offer a rich resource to obtain this knowledge. Here, we present an...
8.
Schachter N, Adams J, Skowron P, Kozma K, Lee C, Raghuram N, et al.
Nat Commun
. 2021 Sep;
12(1):5238.
PMID: 34475389
The most common events in breast cancer (BC) involve chromosome arm losses and gains. Here we describe identification of 1089 gene-centric common insertion sites (gCIS) from transposon-based screens in 8...
9.
Rogers L, Wang Z, Mott S, Dupuy A, Weiner G
Cancer Immunol Res
. 2020 Jul;
8(9):1206-1214.
PMID: 32611665
T-cell-mediated cancer immunotherapies, including anti-PD-1 and T cells expressing chimeric antigen receptors (CAR-T cells), are becoming standard treatments for many cancer types. CAR-T therapy, in particular, has been successful in...
10.
Vanneste M, Feddersen C, Varzavand A, Zhu E, Foley T, Zhao L, et al.
Front Oncol
. 2020 Apr;
10:442.
PMID: 32346533
Patients with malignant melanoma have a 5-year survival rate of only 15-20% once the tumor has metastasized to distant tissues. While MAP kinase pathway inhibitors (MAPKi) are initially effective for...